In a report issued on April 27, Rahul Sarugaser from Raymond James maintained a Buy rating on Indiva (NDVAF – Research Report), with a price target of C$0.60. The company's shares closed last Friday at $0.19, close to its 52-week low of $0.18. According to TipRanks.com, Sarugaser has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -5.1% and a 30.4% success rate. Sarugaser covers the Healthcare sector, focusing on stocks such as Ginkgo Bioworks Holdings, Decibel Cannabis Company, and Cardiol Therapeutics. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Indiva with a $0.
https://www.tipranks.com/news/blurbs/raymond-james-thinks-indivas-stock-is-going-to-recover?utm_source=advfn.com&utm_medium=referral
Indiva (QX) (USOTC:NDVAF)
Historical Stock Chart
From Jul 2022 to Aug 2022 Click Here for more Indiva (QX) Charts.
Indiva (QX) (USOTC:NDVAF)
Historical Stock Chart
From Aug 2021 to Aug 2022 Click Here for more Indiva (QX) Charts.